BR3003
AssetSmall moleculeAlso BR3003(T), Dapagliflozin/Pioglitazone
Fixed-dose combination of SGLT2 inhibitor dapagliflozin and PPAR-gamma agonist pioglitazone to lower blood glucose.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Insulin/IGF-1 signalling
- Indications
- 4
- Trials
- 636
- Developers
- 1
Indications
4Type 2 diabetes
Phase 3RECRUITINGNCT06972732clinicaltrials.gov7 Oct 2026
Type2 diabetes
Phase 3COMPLETEDNCT04885712clinicaltrials.gov7 Oct 2026
Diabete mellitus
Phase 1RECRUITINGNCT07083401clinicaltrials.gov7 Oct 2026
1 more
- Targets and what it contains6
- Owner and partners1
- Trials636
- Evidence for its targets6
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 6 sources